CDKN2B-AS1 and plasma cell myeloma: PCAT1, ANRIL, H19, ANGPTL1‐3, or NEAT1 upregulation induced myeloma cells insensitive to bortezomib, whereas CRNDE overexpression leads to dexamethasone tolerance.